Gopal V, Hulette B, Li Y Q, Kuvelkar R, Raza A, Larson R, Goldberg J, Tricot G, Bennett J, Preisler H
University of Cincinnati Medical Center, Ohio 45267-0508.
Leuk Res. 1992 Oct;16(10):1003-11. doi: 10.1016/0145-2126(92)90080-q.
Monoclonal antibodies and flow cytometry were used to detect the expression of c-myc and c-myb in the bone marrow (BM) and peripheral blood (PB) cells of patients with acute myelogenous leukemia (AML). The expression of neither gene was correlated with the percent blast cells in the BM or PB nor was there a correlation between c-myc and c-myb expression. A wide range of expression of each gene was found within each FAB type of AML. Patients who had a high proportion of leukemia cells expressing c-myb were less likely to respond to remission induction therapy than patients in whom a low proportion of cells expressed c-myb. This association appears to reflect an inverse relationship between the proportion of cells expressing c-myb and the sensitivity of leukemia cells to the killing effects of chemotherapy in vivo. Treatment outcome was unrelated to c-myc expression.
采用单克隆抗体和流式细胞术检测急性髓系白血病（AML）患者骨髓（BM）和外周血（PB）细胞中c-myc和c-myb的表达。这两个基因的表达均与BM或PB中的原始细胞百分比无关，c-myc和c-myb的表达之间也没有相关性。在每种FAB分型的AML中均发现每个基因的表达范围很广。与c-myb表达细胞比例低的患者相比，c-myb表达白血病细胞比例高的患者对缓解诱导治疗的反应可能性较小。这种关联似乎反映了表达c-myb的细胞比例与体内白血病细胞对化疗杀伤作用的敏感性之间的负相关关系。治疗结果与c-myc表达无关。
